Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Slowing Progression of Retinal Diseases by Blocking Fas Receptor on the Surface of Retinal Cells with David Esposito ONL Therapeutics TRANSCRIPT
Download PDFSep 12, 2023
David Esposito, President and CEO of ONL Therapeutics, is focused on back-of-the-eye diseases such as open-angle glaucoma, dry age-related macular degeneration, and retinal detachment. Their drug ONL1204 targets retina cells to block the Fas receptor to reduce damage to the eye. This small peptide is delivered via an...
Sep 12, 2023
David Esposito, President and CEO of ONL Therapeutics, is focused on back-of-the-eye diseases such as open-angle glaucoma, dry age-related macular degeneration, and retinal detachment. Their drug ONL1204 targets retina cells to block the Fas receptor to reduce damage to the eye. This small peptide is delivered via an...
Using Therapeutic Peptides to Treat Permanent Hypoparathyroidism with Mark Sumeray MD Amolyt Pharma TRANSCRIPT
Download PDFDec 27, 2022
Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating...
Dec 27, 2022
Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating...
Developing Antibacterial Peptide to Treat Periprosthetic Joint Infection with Dr. David Huang Peptilogics TRANSCRIPT
Download PDFDec 19, 2022
Dr. David Huang is Senior VP and Chief Medical Officer at Peptilogics and working to change the approach for treating and reducing reinfection rates of periprosthetic joint infection, PJI. Their lead highly charged peptide PLG0206 has been shown to be broad spectrum and active against multi-drug resistant bacteria,...